Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M A Pfaller

Showing results (291-300 of 542) with videos related to

Pageof 55
Sort By:
Diagnostic Microbiology and Infectious Disease|March 26, 1999
In vitro pharmacodynamic properties of MK-0991 determined by time-kill methodsE J Ernst, M E Klepser, M E Ernst, et al.
Diagnostic Microbiology and Infectious Disease|November 1, 2001
Neisseria meningitidis with decreased susceptibility to penicillin: report from the SENTRY antimicrobial surveillance program, North America, 1998-99S S Richter, K A Gordon, P R Rhomberg, et al.
Journal of Clinical Microbiology|January 9, 2003
Evaluation of Etest method for determining voriconazole and amphotericin B MICs for 162 clinical isolates of Cryptococcus neoformansM J Maxwell, S A Messer, R J Hollis, et al.
The Journal of Antimicrobial Chemotherapy|January 30, 2002
Comparison of Etest, chequerboard dilution and time-kill studies for the detection of synergy or antagonism between antifungal agents tested against Candida speciesR E Lewis, D J Diekema, S A Messer, et al.
Antimicrobial Agents and Chemotherapy|May 23, 2002
In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida sppM A Pfaller, S A Messer, R J Hollis, et al.
Antimicrobial Agents and Chemotherapy|May 21, 1998
Influence of test conditions on antifungal time-kill curve results: proposal for standardized methodsM E Klepser, E J Ernst, R E Lewis, et al.
Antimicrobial Agents and Chemotherapy|June 13, 1998
Assessment of antifungal activities of fluconazole and amphotericin B administered alone and in combination against Candida albicans by using a dynamic in vitro mycotic infection modelR E Lewis, B C Lund, M E Klepser, et al.
Diagnostic Microbiology and Infectious Disease|December 24, 1997
An outbreak of Candida parapsilosis prosthetic valve endocarditisD J Diekema, S A Messer, R J Hollis, et al.
Diagnostic Microbiology and Infectious Disease|February 12, 1998
Nosocomial streptococcal blood stream infections in the SCOPE Program: species occurrence and antimicrobial resistance. The SCOPE Hospital Study GroupM A Pfaller, R N Jones, S A Marshall, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|February 1, 1994
Quality control parameters for broth microdilution susceptibility testing of amoxicillin and amoxicillin-clavulanic acidA L Barry, S D Allen, P C Fuchs, et al.
Pageof 55

Showing results (291-300 of 542) with videos related to

Sort By:
Pageof 55
Diagnostic Microbiology and Infectious Disease|March 26, 1999
In vitro pharmacodynamic properties of MK-0991 determined by time-kill methodsE J Ernst, M E Klepser, M E Ernst, et al.
Diagnostic Microbiology and Infectious Disease|November 1, 2001
Neisseria meningitidis with decreased susceptibility to penicillin: report from the SENTRY antimicrobial surveillance program, North America, 1998-99S S Richter, K A Gordon, P R Rhomberg, et al.
Journal of Clinical Microbiology|January 9, 2003
Evaluation of Etest method for determining voriconazole and amphotericin B MICs for 162 clinical isolates of Cryptococcus neoformansM J Maxwell, S A Messer, R J Hollis, et al.
The Journal of Antimicrobial Chemotherapy|January 30, 2002
Comparison of Etest, chequerboard dilution and time-kill studies for the detection of synergy or antagonism between antifungal agents tested against Candida speciesR E Lewis, D J Diekema, S A Messer, et al.
Antimicrobial Agents and Chemotherapy|May 23, 2002
In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida sppM A Pfaller, S A Messer, R J Hollis, et al.
Antimicrobial Agents and Chemotherapy|May 21, 1998
Influence of test conditions on antifungal time-kill curve results: proposal for standardized methodsM E Klepser, E J Ernst, R E Lewis, et al.
Antimicrobial Agents and Chemotherapy|June 13, 1998
Assessment of antifungal activities of fluconazole and amphotericin B administered alone and in combination against Candida albicans by using a dynamic in vitro mycotic infection modelR E Lewis, B C Lund, M E Klepser, et al.
Diagnostic Microbiology and Infectious Disease|December 24, 1997
An outbreak of Candida parapsilosis prosthetic valve endocarditisD J Diekema, S A Messer, R J Hollis, et al.
Diagnostic Microbiology and Infectious Disease|February 12, 1998
Nosocomial streptococcal blood stream infections in the SCOPE Program: species occurrence and antimicrobial resistance. The SCOPE Hospital Study GroupM A Pfaller, R N Jones, S A Marshall, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|February 1, 1994
Quality control parameters for broth microdilution susceptibility testing of amoxicillin and amoxicillin-clavulanic acidA L Barry, S D Allen, P C Fuchs, et al.
Pageof 55